Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.04), Morningstar.com reports. Aurinia Pharmaceuticals had a negative return on equity of 30.34% and a negative net margin of 12,536.05%. The firm had revenue of $0.38 million for the quarter, compared to analysts’ expectations of $0.07 million.

NASDAQ:AUPH traded up $0.05 during trading hours on Friday, hitting $5.65. 883,496 shares of the stock were exchanged, compared to its average volume of 444,432. Aurinia Pharmaceuticals has a 52-week low of $4.41 and a 52-week high of $6.69. The firm has a market cap of $476.10 million, a P/E ratio of -6.14 and a beta of 2.22.

Several research firms have commented on AUPH. Zacks Investment Research upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.75 price objective for the company in a research note on Monday, July 16th. Cantor Fitzgerald set a $18.00 price objective on Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, October 1st. BidaskClub lowered Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, August 8th. HC Wainwright boosted their price objective on Aurinia Pharmaceuticals to $15.00 and gave the stock a “buy” rating in a research note on Monday, August 13th. Finally, ValuEngine upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 28th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $11.79.

A number of large investors have recently bought and sold shares of AUPH. BlackRock Inc. boosted its holdings in shares of Aurinia Pharmaceuticals by 45.2% during the 1st quarter. BlackRock Inc. now owns 1,045,121 shares of the biotechnology company’s stock worth $5,424,000 after purchasing an additional 325,408 shares during the last quarter. FMR LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 2.1% during the 3rd quarter. FMR LLC now owns 4,680,959 shares of the biotechnology company’s stock worth $31,082,000 after purchasing an additional 95,650 shares during the last quarter. Stanley Laman Group Ltd. acquired a new position in shares of Aurinia Pharmaceuticals during the 2nd quarter worth approximately $276,000. Ironwood Investment Management LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 18.0% during the 2nd quarter. Ironwood Investment Management LLC now owns 218,568 shares of the biotechnology company’s stock worth $1,231,000 after purchasing an additional 33,279 shares during the last quarter. Finally, Creative Planning boosted its holdings in shares of Aurinia Pharmaceuticals by 8.2% during the 2nd quarter. Creative Planning now owns 171,200 shares of the biotechnology company’s stock worth $964,000 after purchasing an additional 13,000 shares during the last quarter. Institutional investors own 24.87% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Aurinia Pharmaceuticals (AUPH) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2018/11/10/aurinia-pharmaceuticals-auph-releases-quarterly-earnings-results-misses-estimates-by-0-04-eps.html.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Featured Story: How does a reverse stock split work?

Earnings History for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.